Low Testosterone News and Research

RSS
Lilly's Axiron testosterone replacement therapy now available in US pharmacies

Lilly's Axiron testosterone replacement therapy now available in US pharmacies

Endo's FORTESTA Gel for treatment of 'Low T' in males is now available in pharmacies

Endo's FORTESTA Gel for treatment of 'Low T' in males is now available in pharmacies

Endo fourth quarter total revenues increase 31% to $511 million

Endo fourth quarter total revenues increase 31% to $511 million

Longer life with osteoporosis therapy: Study

Longer life with osteoporosis therapy: Study

Lipocine files new patent applications in support of oral testosterone product for hypogonadism

Lipocine files new patent applications in support of oral testosterone product for hypogonadism

Repros receives IRB approval for Androxal Phase IIb study in secondary hypogonadism

Repros receives IRB approval for Androxal Phase IIb study in secondary hypogonadism

FDA approves Endo's FORTESTA Gel for low testosterone

FDA approves Endo's FORTESTA Gel for low testosterone

Research programs embody the promise of anti-aging medicine.

Research programs embody the promise of anti-aging medicine.

Frisky old men - still keen and active:  Sex study

Frisky old men - still keen and active: Sex study

FDA approves Axiron topical solution CIII for testosterone replacement therapy in men

FDA approves Axiron topical solution CIII for testosterone replacement therapy in men

ESF report: Reduced male fertility may contribute to low birth rates

ESF report: Reduced male fertility may contribute to low birth rates

Testosterone treatment for frailty in older men lacks long term benefits

Testosterone treatment for frailty in older men lacks long term benefits

UB endocrinologist receives Junior Faculty Award to study effects of low testosterone in young men with type 2 diabetes

UB endocrinologist receives Junior Faculty Award to study effects of low testosterone in young men with type 2 diabetes

Repros commences randomization in Androxal Phase II study in T2DM men with low testosterone

Repros commences randomization in Androxal Phase II study in T2DM men with low testosterone

Link between low testosterone and heart disease deaths: Study

Link between low testosterone and heart disease deaths: Study

Low level of testosterone increases risk for Alzheimer's disease

Low level of testosterone increases risk for Alzheimer's disease

Low testosterone levels to blame for low libido, fatigue and weight gain

Low testosterone levels to blame for low libido, fatigue and weight gain

Repros Therapeutics requests Type B Meeting to review Androxal Phase III protocols

Repros Therapeutics requests Type B Meeting to review Androxal Phase III protocols

Repros receives US patent for Androxal

Repros receives US patent for Androxal

Repros Therapeutics second-quarter net loss decreases to $1.3 million

Repros Therapeutics second-quarter net loss decreases to $1.3 million